All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Join our
Treating classical Hodgkin lymphoma: Spotlight on targeted therapies
with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce
Saturday, November 2, 2024
8:50-9:50 CET
This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.
Gilles SallesChair
Professor Gilles Salles, the Chair of the Lymphoma Hub, is Chief of the Lymphoma Service at the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, US. Professor Gilles Salles chaired the Hematology Department of the Centre Hospitalier Lyon-Sud, Lyon, FR, from 2011 until 2020, when he took on his current role as Head of Department at Memorial Sloan Kettering Cancer Center.
After training in Centre Hospitalier Lyon-Sud and a post-doctoral fellowship at Harvard Medical School (Dana-Farber Cancer Institute, Boston, US), Prof. Salles has been working in the field of lymphoma clinical research with the following specific interests:
- Identification and validation of new prognostic factors for lymphoma
- Clinical trials, especially in follicular lymphoma patients (serving, amongst others, as the Principal Investigator of the largest academically randomized clinical trial in patients with follicular lymphoma — PRIMA)
- Development of novel drugs, and preclinical research
Positions of responsibility/awards:
- Deputy Editor (Lymphoma) of Haematologica (2001–2003)
- Chair of the Leukemia Selection Committee of the Fondation de France (2005–2008)
- Chair of the Scientific Program Committee of the European Hematology Association (EHA) for its 13th Annual Congress (2008)
- Professor of Medicine at Université Claude Bernard, Lyon, Faculté Lyon Sud – Charles Mérieux (1996–2020)
- Chair of the Clinical Hematology Department at Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud (2011–2020)
- Chair of the Scientific Committee of the French-Belgium cooperative Group GELA (Groupe d’Etude des Lymphomes des L’Adulte) (1996–2007)
- Chair of the European Cooperative Group LYSA (the Lymphoma Study Association) (2012–present)
- Vice-president for research at the Board of Directors of Hospices Civils de Lyon (2010–2016)
- Chair of the Coordinating Committee for Biomedical Research and Public Health of the Hospices Civils de Lyon (2007–2009, 2013–2016)
- Project leader and Chair of the Administrative Board of the Institut Carnot CALYM (Consortium for the Acceleration of Innovation in Lymphoma) (2011–present)
- Chair of the Lymphoma Hub (2014–present)